It’s been 20 years since the FDA approved the first glucagon-like peptide-1 receptor agonist (GLP-1RA), fundamentally transforming how type 2 diabetes (T2D) is treated. A decade later, the approval of another GLP-1RA, liraglutide, for obesity management marked another critical milestone.

Today, GLP-1RAs sit at the heart of a global healthcare conversation. One that reaches far beyond endocrinology and into public policy, supply chains, and even pop culture.

Despite some current controversy around access, cost, and safety, GLP-1RA medicine has gained popularity for good reason: it has transformed the ability for millions of people across the world to manage their diabetes and obesity. And the next decade of GLP-1RA medicine portends even greater transformation to healthcare. The wor

See Full Page